To the Editor.
—Several case-control studies of cataract have identified aspirin consumption as a protectant against cataract. These findings need to be tested in a clinical trial to determine the role of aspirin therapy in retarding cataract. Since no such trial has been undertaken, the next best approach has appeared to be a piggyback study on a major study of the effects of aspirin therapy on myocardial infarction, as reported in the February 1991 issue of the Archives.1 Results of the study of 22 071 male physicians had shown a significant protective effect of aspirin against myocardial infarction but not against total cardiovascular deaths. In this article, cataract extraction was found to be less frequent in the aspirin-taking group than in the placebo group, but the difference was not statistically significant. Therefore, the authors concluded that aspirin had no large benefit in protecting against cataract, contrary to the
Harding JJ. Aspirin and Cataract. Arch Ophthalmol. 1991;109(10):1344. doi:10.1001/archopht.1991.01080100024010